Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients

van Leth, 2004, Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study., Lancet, 363, 1253, 10.1016/S0140-6736(04)15997-7

Cooper, 2007, Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review., HIV Med, 8, 1, 10.1111/j.1468-1293.2007.00426.x

Pocock, 2003, The pros and cons of noninferiority trials., Fundam Clin Pharmacol, 17, 483, 10.1046/j.1472-8206.2003.00162.x

Cheeseman, 1993, Pharmacokinetics of nevirapine: initial single-rising-dose study in humans., Antimicrob Agents Chemother, 37, 178, 10.1128/AAC.37.2.178

Kappelhoff, 2005, Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study., HIV Clin Trials, 6, 254, 10.1310/B5VU-FU5F-QNWC-UDCK

van Heeswijk, 2000, The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals., AIDS, 14, F77, 10.1097/00002030-200005260-00001

Almond, 2004, The relationship between nevirapine plasma concentrations and abnormal liver function tests., AIDS Res Hum Retroviruses, 20, 716, 10.1089/0889222041524670

Kappelhoff, 2005, Are adverse events of nevirapine and efavirenz related to plasma concentrations?, Antivir Ther, 10, 489, 10.1177/135965350501000404

Kappelhoff, 2005, Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study., Antivir Ther, 10, 145, 10.1177/135965350501000114

Garcia, 2000, Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study., AIDS, 14, 2485, 10.1097/00002030-200011100-00010

Raffi, 2000, The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults., Antivir Ther, 5, 267, 10.1177/135965350000500405

Negredo, 2004, Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach., Antivir Ther, 9, 335, 10.1177/135965350400900304

Shenton, 2003, Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat., Chem Res Toxicol, 16, 1078, 10.1021/tx034064+

Maggiolo, 2007, Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort., J Antimicrob Chemother, 59, 569, 10.1093/jac/dkl534

Parienti, 2007, Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study., AIDS, 21, 2217, 10.1097/QAD.0b013e3282eff388